Abstract -Nano-sized objects interact with biological systems in fundamentally novel ways, thereby holding great promise for targeted drug-delivery. It has also been suggested they could constitute a hitherto unseen hazard. Numerous experimental studies in the field are taking place. We consider that the nature of the interactions allows a more fundamental theoretical framework to be developed. In particular, we describe the intimate link that develops between nanoparticle uptake and cell population evolution. Explicit analytical results are given and the theory compared to experimental observations.
Introduction. -The interactions between nano-sized objects, nanoparticles, and living organisms is currently under intense study [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . The nanoscale is privileged because many endogenous biological processes (for example, internalisation and trafficking of cargoes in cells [13] ) operate on the scale of tens of nanometres. Engineered nanoparticles can thereby engage with biological processes in fundamentally new manners [2] [3] [4] 14] . In particular, nanoparticles can be directed to, and accumulated in, specific locations within organisms using the cell's energy, unlike small molecules that partition according to basic physicochemical equilibrium principles [15] . These nonequilibrium cell-energy dependent processes are not microscopically reversible, and have suggested a potentially new paradigm of interest for medicines [16] [17] [18] [19] . Thus, very small amounts of drugs can be sent to specific locations, rather than rely on the imperfect control of physicochemical properties of molecules to achieve a (quasi-equilibrium) partitioning within the organism, this usually limiting the dose of the medicine that can be delivered.
Nanoparticles associated with the cell surface are imported within small nanoscale capsules (endosomes) and are carried into and within the cell by endogenous cellular processes [20] . Unlike the situation for molecules, there is no reversibility in the transport across the cell membrane. Thus, unless they are specifically recognized for that purpose, nanoparticles are typically not exported out of the cell [1, 15, 21] and accumulate in organelles inside the cell [15, 20, 21] . If the nanoparticles are slow to degrade inside the cell (as many engineered nanoparticles are) they will accumulate until split between daughter cells when the cell divides [1, 15, 22] . Indeed, most cells divide somewhat, even if (as for instance cells in the brain) very slowly. The cells used in laboratories, however, divide rapidly. Cancer cells share this property, leading to unique challenges for therapeutics, for in this case the division of the cells competes with the accumulation of nanoparticles.
Here we show that the absence of equilibration processes, when coupled to ageing and division of individual cells, leads to a predictable history-dependent nanoparticle amount within each cell. In experiments it is possible to measure these amounts individually in great numbers of cells, but more commonly it is the average that is reported, and this has hitherto obscured many of the fundamental details of the processes. We define appropriate ensembles in order to link properties of single cells to their macroscopic averages, and compare to experimental data.
The model. -The time a cell spends between divisions is referred to as the 'cell cycle', and it is divided into four stages ('phases') G 1 , S, G 2 and M [ fig. 1(a) ], of distinct biochemical and morphological activity [23] . In a typical laboratory experiment, many thousands of cells p-1 are asynchronously progressing through this cell cycle in a relatively independent manner. Models of the cell cycle based on reaction networks exist (see e.g. ref. [24] ), but are not necessary for nanoparticle accumulation studies. We have advanced a simpler model (similar to ref. [25] ) that can be solved analytically. Assume that all cells in a population age at the same rate and spend the same amount of time, T , between divisions. If f (τ, m, t)dτ dm denotes the number of cells of 'age' τ (time elapsed since last division) that contain m nanoparticles, the continuity equation in this space reads
where J is the uptake rate of nanoparticles by cells. We neglect interactions among neighbouring cells and cell death, all reasonable for experiments currently of interest, but these elements could in principle be accommodated.
For several nanoparticle/cell systems studied experimentally there is no export of nanoparticles from the cells [1, 15, 21] , and the intracellular nanoparticles are split between daughter cells upon division [1, 15, 22] . For such systems f (τ, m, t) fulfills the boundary condition
where Θ(m ′ , m) is the probability that upon division one of the daughters receives m, if the original cell has m ′ , nanoparticles. Experiments indicate (assuming a binomial distribution) nanoparticle-containing endosomes splitting asymmetrically [22] , but below we illustrate with the case of both daughters receiving half of the nanoparticles of the original cell, i.e. Θ(m
Cell cycle. -Equations (1)- (2) is our basic framework that has to be solved for initial conditions of interests. We start by relating and validating the model to experimental observations of cell population growth and cell cycle progression. Thus we ignore cellular nanoparticle amount (for the moment), and let n(τ, t) = f (τ, m, t)dm denote the reduced distribution. The total number of cells, N (t) = T 0 n(τ, t)dτ , grows monotonically and steadystate solutions (with n(τ, t)/N (t) time independent) have the form n(τ, t) = 2λe −λτ N (t) ≡ 2λe −λτ N 0 e λt , where N 0 is the initial total number of cells and λT = ln 2. Steadystate solutions exhibit exponential growth, typical of experimental cell cultures studied in the laboratory. The total duration of the cell cycle, T , can consequently be evaluated experimentally. Figure 1(c) shows the steadystate distribution, from which we observe that the duration of a phase can be related to the fraction of cells in it [26] . The fraction of cells in a phase can be readily measured, and thus all parameters of the cell cycle model can be fixed by experiment. To make explicit connection with experiments, we will in the following use parameters appropriate for A549 (human lung carcinoma) cells in our illustrations of the theory. In this case we have previously Having fixed all parameters by experiment, we can validate the model by subsequent parameter-free studies. For our example of A549 cells we have previously measured the fraction of cells that divide with time [1] , as shown in fig.  1 (d) together with the corresponding theoretical prediction. The striking agreement constitutes a firm basis for the future development of the model to include nanoparticle accumulation. It is noteworthy that considerable efforts have been made experimentally to gather data of high quality to enable such quantitative agreement.
Nanoparticle accumulation inside cells following short-time (pulse) exposure to nanoparticles.
-Having validated the cell cycle part of the model, we continue with the effect the cell cycle has on nanoparticle accumulation. Essentially, our interest concerns how cellcycle traversal affects the number of nanoparticles per cell, and how to define ensembles useful for experimental comparison. We start with cells exposed to nanoparticles for a limited time (a pulse), short compared to the cell population evolution [ fig. 2(a) ]. Solutions to eqs. (1)- (2) with zero flux, J = 0, naturally show a constant total number of nanoparticles, M (t) = mf (τ, m, t)dmdτ , after nanoparticle exposure. The mean number of nanoparticles per cell, M (t)/N (t), consequently decays exponentially for a cell population growing exponentially.
Experimental studies have reported this seemingly simple exponential decay of the mean amount of nanoparticles per cell, but during the averaging procedure a more complex evolution in terms of individual cell cycle phases is lost. The full distribution, f (τ, m, t), gives a complete theoretical description of the process. Interestingly, f (τ, m, t) is also essentially experimentally observable, in the sense that we only need to convert the τ -dependence into a dependence on DNA amount (see ref. [27] for details). lated polystyrene nanoparticles. Experimentally the initial cellular nanoparticle amount is heterogeneous among cells from the same population (left), which is easily incorporated into the model (see below). However, we also observe the characteristic decay of nanoparticle concentration [ fig. 2(d) ] as predicted by the model [ fig. 2(c) ]. The decay of nanoparticle fluorescence is directly correlated to DNA amount, supporting further the idea that p-3 reduction of nanoparticle amount arises from cell division, rather than export out of cells.
Nanoparticle uptake during continuous exposure. -The more usual laboratory experiment involves continuous exposure of cells [ fig. 3(a) ] to an excess of nanoparticles so that the ambient concentration remains constant. We then have nanoparticle fluxes into cells per unit time, J(τ, m, t), with the independent variables reflecting biological and other details (e.g. the number of receptors, cell surface area and current number of internalised nanoparticles). Current evidence suggests that J is independent of m and t. To investigate uptake rates that are different among cell cycle phases we, however, let J(τ ) depend on the instantaneous phase of the cell, parametrised by τ . The mean nanoparticle amount of the full population (growing exponentially) is then given by M (t)/N (t) = M (t) = J 1 − e −λt /λ [15] . Here the ensemble-averaged mean uptake rate, J = J G1 u G1 + J S u S + J G2/M u G2/M , for uptake rates, J φ , that are constant within each phase, φ, and u φ is the fraction of cells in φ. Again, this development of the theory is formulated such that all parameters are experimentally measurable to facilitate a close connection to experiments. Figure 3(b) shows that the mean uptake is initially linear (dotted line), while for times comparable to the cell cycle length, uptake competes with reduction of nanoparticle amount due to cell division (solid line). Both observations are corroborated experimentally [1, 15, 21] , as exemplified in fig. 3 (b) (inset) for A549 cells exposed to 40 nm (diameter) fluorescently labelled carboxylated polystyrene nanoparticles. Asymptotically, one observes a constant mean cellular nanoparticle amount, J /λ. Presently there is some uncertainty in the literature as to the origin of the non-linear nanoparticle uptake kinetics; we believe that, typically, rather than competition between nanoparticle uptake and export leading to a steady state, one is observing the mechanism described here.
The mean intracellular nanoparticle amount of individual phases, M φ (t)/N φ (t), exhibits more complex behaviour. Depending on the nanoparticle uptake rates during individual phases, J φ , the behaviour can vary greatly, as shown in fig. 3(c) for some example sets of rates and with cell cycle parameters appropriate for A549 cells. If the cellular impact of nanoparticles is related to the intracellular nanoparticle concentration, then these different accumulations can have many practical outcomes, yet to be analysed. For the case of A549 cells exposed to 40 nm (diameter) fluorescently labelled carboxylated polystyrene nanoparticles, the uptake rates are roughly independent of phase. The theory [ fig. 3(c) left] then predicts that the cellular nanoparticle amount is ranked: G 2 /M > S > G 1 , an observation that is indeed validated by experiments on these cells [1] .
The full distribution, f (τ, m, t), gives the complete picture, in essence carrying the complete history of nanoparticle accumulation and cell division. To have an illustration that is closer to experiment, we again evaluate this distribution in terms of DNA amount rather than τ . Figure  3 (d) shows this distribution for phase-independent uptake rates and both daughter cells receiving half of the intracellular nanoparticles upon division.
Cells not yet divided move continuously towards higher nanoparticle amounts, simultaneously reducing in number as cells progressively divide. Divided cells have instead taken up some nanoparticles prior to division and some after; recently divided cells have half, while cells that divided early almost the same, nanoparticle amount as cells not yet divided. After p-4 fig. 1(c) ].
For detailed comparisons with experiments, the large heterogeneity in nanoparticle uptake kinetics within the cell population must be taken into account. In the simplest case of phase-independent uptake rates (which is relevant for our previous experiment [1] ), we let f J (J) denote the normalised distribution in rates. For simplicity, we assume that both daughter cells inherit the uptake capacity of the original cell; thus, f J (J) is time-independent. Uptake rate heterogeneity can be included by integrating previous results with f J (J) as a kernel, most results remaining valid. As an explicit illustration we compare with our previous experimental results on A549 cells exposed to 40 nm (diameter) fluorescently labelled carboxylated polystyrene nanoparticles [ fig. 4(b) ] by using cell cycle parameters appropriate for these cells. We, furthermore, utilize a log-normal distribution in uptake as proposed previously [28] and adjust the parameters such that the distribution of nanoparticle amount, µ ( m, t) = f (τ, m, t)dτ , of the full population agrees with experiments. Subsequently the theory gives a parameter-free prediction of the distribution of nanoparticle amount in the different cell cycle phases, µ φ (m, t) = f (τ, m, t)dτ , as shown in fig. 4(a) . The striking agreement with the experimental data [ fig. 4(b) ] suggests that careful experimental studies will be able to recover also the more detailed predictions described above.
Targeting of fast-dividing cells and therapeutics.
-We reiterate how different the processing of nanoparticles by cells is compared to small molecules. This will be reflected in optimal choices for nanoparticle-based cancer therapeutics, but interestingly, no theoretical framework has been developed. For small molecules the capacity to equilibrate across the plasma membrane typically ensures rapid equilibration of drug into the cell, even as it is dividing. Nanoparticles have the merit that their trafficking properties are so well regulated by the cell (requiring explicit signals for export) that they accumulate irreversibly. Naturally at some point the drug may be released from its nanoform inside the cell, but this cannot make the situation more favourable (molecules will partition to the outside of the cell) and the basic mechanism of cell division dilutes the intracellular nanoparticle content.
We now have a simple model that is able to quantitatively reproduce nanoparticle accumulation for fastdividing cells, and can use it to predict and optimise cancer targeting strategies. Naturally there are (in vivo) other complicating factors, but the basic understanding derived from the present model yields various insights, not yet appreciated. For cancer-targeting the aim is to achieve a higher dose in fast-dividing (cancerous) cells compared to slow-dividing (healthy) cells. Treating the healthy cells as essentially non-dividing and assuming a linear nanoparticle uptake for them, the targeting efficiency (the ratio of nanoparticle content in cancerous to healthy cells)
−λt /(λt). We might for example target cells in the S, G 2 and/or M phases [1] , since non-dividing cells do not pass through these phases. For this case we write J c = (1 − α) J h + α J t , where α is the fraction of cells in the targeted phases and J t the flux into them. We have assumed (for simplicity) that cells in the remaining phase(s) take up nanoparticles at the same rate as non-dividing cells. Figure 5a shows the targeting efficiency as a function of time, using parameters (as validated in connection with fig. 1 ) suitable for targeting S phase A549 cells for definiteness. It is clear that regardless of how large a flux ratio, J t / J h , is achieved, eventually the mean dose of the non-dividing cell population exceeds that of the dividing population, an unfavourable outcome from the therapeutic perspective, though of course it is intended that the nanoparticle-carried therapy be released inside the cell at an appropriate time. A relevant time-scale is set by the retention time of nanoparticles in the body (i.e., the time that nanoparticles circulate in the bloodstream and are exposed to the tumour). Figure 5b shows the necessary flux ratios that must be achieved for successful targeting for some realistic nanoparticle retention times. For example, to obtain a ten-fold excess of nanoparticle accumulation in cancer cells during 24 h, a 34 times higher flux into (in this illustration) S phase cells must be achieved. The model places rather concrete bounds on the enhancements of rates of cancer compared to normal cell entry required for a meaningful approach, and can also suggest an ideal time at which the drug should be released inside the cell.
Discussion. -In summary, we emphasise that nanoparticles interacting with cells represent entirely new systems which can be described theoretically, and will likely be the topic of greatly increased modelling in the coming years. Until now, in the absence of any guiding theoretical framework, the averaging of cellular readouts over inappropriate ensembles has been adopted, without alteration, from small molecule-cell interactions. However, the non-equilibrium uptake of nanoparticles leads to each cell having a history-dependent nanoparticle amount based on its cell cycling. We have shown that in future all cellular effects (based on intracellular concentration) of nanoparticles should be appropriately averaged over the cell-cycle ensembles, and provided the machinery to do so. This would put the whole arena of nanoparticle-cell interactions on a more secure basis, and possibly eliminate current apparent inconsistency in experiments.
